These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26270251)

  • 1. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.
    VanderBeek BL; Bonaffini SG; Ma L
    Ophthalmology; 2015 Nov; 122(11):2311-2315.e1. PubMed ID: 26281823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
    Ng DS; Kwok AK; Chan CW; Li WW
    Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
    Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endophthalmitis after resident-performed intravitreal bevacizumab injection.
    Falavarjani KG; Aghamirsalim M; Modarres M; Hadavandkhani A; Hashemi M; Parvaresh MM; Naseripour M; Samiy N
    Can J Ophthalmol; 2015 Feb; 50(1):33-6. PubMed ID: 25677280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
    Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections.
    Sharma S; Johnson D; Abouammoh M; Hollands S; Brissette A
    Can J Ophthalmol; 2012 Jun; 47(3):275-9. PubMed ID: 22687306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital.
    Zafar S; Hamid A; Bin Mahmood SU; Burq MA; Maqsood N
    Can J Ophthalmol; 2018 Apr; 53(2):94-97. PubMed ID: 29631833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab.
    Holfinger S; Miller AG; Rao LJ; Rowland DY; Hornik JH; Miller DG
    JAMA Ophthalmol; 2016 Jan; 134(1):45-8. PubMed ID: 26540671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Endophthalmitis after Intravitreal Injections: Risk Factors, Microbiology Profile, and Clinical Outcomes.
    Mishra C; Lalitha P; Rameshkumar G; Agrawal R; Balne PK; Iswarya M; Kannan NB; Ramasamy K
    Ocul Immunol Inflamm; 2018; 26(4):559-568. PubMed ID: 29437495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.